Review Article

Pharmacokinetics of antimicrobials in obese children

Published in: Volume 2 / Year 2013 / Issue 2
Author(s): ,
Page: 76-81

Author byline as per print journal: Mario R Sampson, PharmD; Michael Cohen-Wolkowiez, MD, PhD; Professor Daniel Kelly Benjamin Jr, MD, MPH, PhD; Edmund V Capparelli, PharmD; Kevin M Watt, MD… Read More »

Biosimilars in the European market

Published in: Volume 2 / Year 2013 / Issue 1
Author(s): , , , , ,
Page: 30-5

Author byline as per print journal: Professor Joan Rovira, PhD; Leandro Lindner, BSc; Emmanuel Giménez, BSc; Professor Jaime Espín, PhD; Antonio Olry de Labry, PhD; Leticia García, BSc Introduction and… Read More »

Current status of biopharmaceuticals in Iran’s pharmaceutical market

Published in: Volume 2 / Year 2013 / Issue 1
Author(s):
Page: 26-9

Abstract: The clinical importance of biopharmaceuticals for the management of life threatening diseases is increasing but costs have become a major obstacle to the administration of these medicines, especially in… Read More »

Assessing biosimilarity and interchangeability of biosimilar products under the Biologics Price Competition and Innovation Act

Published in: Volume 2 / Year 2013 / Issue 1
Author(s): ,
Page: 20-5

Abstract: Biological (large molecule) drug products are made via living systems and are complex and variable in nature. As a result, generic forms of biological products, also termed biosimilars in… Read More »

Reference pricing systems in Europe: characteristics and consequences

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s): , ,
Page: 127-131

Author byline as per print journal: Pieter Dylst, PharmD; Professor Steven Simoens, MSc, PhD; Professor Arnold G Vulto, PharmD, PhD Introduction: A reference pricing system is a system that establishes a common reimbursement level… Read More »

Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 69-83

Author byline as per print journal: Brian Godman1,2,3, BSc, PhD; Mohammed Abuelkhair4, PharmD; Agnes Vitry5, PharmD, PhD; Shajahan Abdu4, MD; Marion Bennie6,7, MSc; Iain Bishop7, BSc; Sahar Fahmy4, PhD; Kristina Garuoliene8,… Read More »

What lessons can be learned from the launch of generic clopidogrel?

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 58-68

Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;… Read More »

A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 28-32

Author byline as per print journal: Helle Håkonsen, MScPharm, PhD; Else-Lydia Toverud, MScPharm, PhD Introduction: With a few exceptions, generic drug use has been promoted in western countries by allowing pharmacists to… Read More »

European payer initiatives to reduce prescribing costs through use of generics

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 22-7

Author byline as per print journal:  Brian Godman1,2,3, BSc, PhD; Bjorn Wettermark1,4, MSc, PhD; Iain Bishop5, BSc; Thomas Burkhardt6, MSc; Jurij Fürst7, PhD; Kristina Garuoliene8, MD; Ott Laius9, MScPharm; Jaana E Martikainen10,… Read More »

A patient-centred paradigm for the biosimilars market

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 17-21

Abstract:  The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for… Read More »

Page 3 of 4 « Previous1 2 3 4 Next »
Go Back Print